Results 101 to 110 of about 854,024 (332)

Search for Baryon and Lepton Number Violating Decays of the $\tau$ Lepton [PDF]

open access: yes, 1999
We have searched for five decay modes of the tau lepton that simultaneously violate lepton and baryon number: tau -> anti-proton gamma, tau -> anti-proton pi0, tau -> anti-proton eta, tau -> anti-proton 2pi0, and tau -> anti-proton pi0eta.
A. Anastassov   +211 more
core   +2 more sources

Plasma microRNA Signature as Predictive Marker of Clinical Response to Therapy During Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Despite the availability of effective therapies for Multiple Sclerosis (MS), the unpredictable nature of disease progression and the variability in individual treatment outcomes call for reliable biomarkers. This pilot study aims to investigate the potential of plasma circulating microRNAs (miRNAs) as predictive biomarkers for ...
Fortunata Carbone   +19 more
wiley   +1 more source

Targeting tauopathy with engineered tau-degrading intrabodies [PDF]

open access: yes, 2019
BACKGROUND: The accumulation of pathological tau is the main component of neurofibrillary tangles and other tau aggregates in several neurodegenerative diseases, referred to as tauopathies.
Gallardo, Gilbert   +7 more
core   +1 more source

Resonant Structure of $\tau\to 3\pi\pi^{0}\nu_{\tau}$ and $\tau\to \omega\pi\nu_{\tau}$ Decays

open access: yes, 1999
The resonant structure of the four pion final state in the decay $\tau \to 3\pi\pi^0\nu_\tau$ is analyzed using 4.27 million $\tau^+\tau^-$ pairs collected by the CLEO II experiment.
A. Anastassov   +229 more
core   +1 more source

Correlation Between Irisin and Cognitive Functions in Alzheimer Dementia

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The myokine irisin, a recent positive mediator of exercise in the brain, shows neuroprotective functions against Alzheimer's disease (AD). The association between irisin and cognition has never been explored in a biologically defined cohort of patients.
Patrizia Pignataro   +12 more
wiley   +1 more source

On the generic triangle group [PDF]

open access: yes, 2015
We introduce the concept of a generic Euclidean triangle $\tau$ and study the group $G_\tau$ generated by the reflection across the edges of $\tau$. In particular, we prove that the subgroup $T_\tau$ of all translations in $G_\tau$ is free abelian of ...
Isola, Stefano, Piergallini, Riccardo
core  

A Tale of Two Conditions: Pediatric Brugada Syndrome Unveiled—Navigating the Challenges of Coexisting Arrhythmia and Fever‐Induced ECG Pattern

open access: yesAnnals of Noninvasive Electrocardiology
Background Brugada syndrome (BrS) is an inherited channelopathy characterized by right precordial ST‐segment elevation. This study investigates the clinical and genetic characteristics of children with BrS in Hong Kong. Methods A retrospective review was
Hei‐To Leung   +5 more
doaj   +1 more source

APPLYING LITERARY ETHICAL CRITICISM TO TEACHING READING COMPREHENSION OF LITERARY TEXTS TOWARDS THE GOAL OF DEVELOPING STUDENTS' QUALITIES ACCORDING TO THE 2018 GENERAL EDUCATION PROGRAM

open access: yesTạp chí Khoa học
The article begins by applying moral literary criticism in teaching literary text comprehension and provides an overview of the theory of ethical literary criticism.
Do Thi Thuy Duong
doaj   +1 more source

Cognitive Resilience in Apolipoprotein ε4 Carrier Women Predicted by Neuron‐Derived Extracellular Vesicles

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The Apolipoprotein (APOE) ε4 allele is the strongest genetic risk factor for late‐onset Alzheimer's disease (AD); however, many ε4 carriers remain cognitively intact into old age. Leveraging plasma neuron‐derived extracellular vesicles (NDEVs), we sought to identify biomarkers of cognitive resilience and their interplay with APOE ...
Apostolos Manolopoulos   +17 more
wiley   +1 more source

Tau Immunotherapy [PDF]

open access: yesNeurodegenerative Diseases, 2015
In recent years, tau immunotherapy has advanced from proof-of-concept studies [Sigurdsson EM, NIH R01AG020197, 2001; Asuni AA, et al: J Neurosci 2007;27:9115-9129], which have now been confirmed and extended by us and others. Phase I clinical trials on active and passive tau immunizations are being conducted, with several additional passive tau ...
openaire   +2 more sources

Home - About - Disclaimer - Privacy